BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 28236856)

  • 1. Could mucin 16 and colony-stimulating factor 2-receptor beta possible graft versus host disease biomarkers? Medical hypotheses.
    Souza MM; de Paula FM; Hsieh R; Macedo MC; Corral MA; Nunes TB; De Paula F; Lourenço SV
    Med Hypotheses; 2017 Mar; 100():89-93. PubMed ID: 28236856
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Application of proteomics to graft-versus-host disease: from biomarker discovery to potential clinical applications.
    Presland RB
    Expert Rev Proteomics; 2017 Nov; 14(11):997-1006. PubMed ID: 28974115
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Accurate diagnosis of acute graft-versus-host disease using serum proteomic pattern analysis.
    Srinivasan R; Daniels J; Fusaro V; Lundqvist A; Killian JK; Geho D; Quezado M; Kleiner D; Rucker S; Espina V; Whiteley G; Liotta L; Petricoin E; Pittaluga S; Hitt B; Barrett AJ; Rosenblatt K; Childs RW
    Exp Hematol; 2006 Jun; 34(6):796-801. PubMed ID: 16728285
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Salivary proteomic analysis and acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
    Chiusolo P; Giammarco S; Fanali C; Bellesi S; Metafuni E; Sica S; Iavarone F; Cabras T; Messana I; Leone G; Castagnola M
    Biol Blood Marrow Transplant; 2013 Jun; 19(6):888-92. PubMed ID: 23529013
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Allogeneic hematopoietic transplantation with stem cells extracted from peripheral blood].
    Kusminsky G; Foncuberta MC; Aversa L; Drelichman G; Freigeiro D; Burgos R; Irrazabal C; Gonzalez G; Dictar M; Niborski R; Kohan A; Sanchez Avalos JC
    Medicina (B Aires); 2000; 60(2):179-87. PubMed ID: 10962806
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pre-engraftment graft-versus-host disease after allogeneic hematopoietic cell transplantation for acute leukemia.
    Lee JH; Lee JH; Kim DY; Yun SC; Kim SD; Choi Y; Lee YS; Kang YA; Jeon MJ; Seol M; Lee KH
    Eur J Haematol; 2011 Aug; 87(2):172-81. PubMed ID: 21599753
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High alloreactivity of low-dose prophylactic donor lymphocyte infusion in patients with acute leukemia undergoing allogeneic hematopoietic cell transplantation with an alemtuzumab-containing conditioning regimen.
    Liga M; Triantafyllou E; Tiniakou M; Lambropoulou P; Karakantza M; Zoumbos NC; Spyridonidis A
    Biol Blood Marrow Transplant; 2013 Jan; 19(1):75-81. PubMed ID: 22871557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rapid engraftment after allogeneic transplantation of density-enriched peripheral blood CD34+ cells in patients with advanced hematologic malignancies.
    Cao TM; Kusnierz-Glaz C; Valone F; Stockerl-Goldstein KE; Hu WW; Johnston L; Blume KG; Strober S; Negrin RS
    Cancer; 2001 Jun; 91(12):2205-13. PubMed ID: 11413507
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical outcomes and graft characteristics in pediatric hematopoietic stem cell transplantation: Effect of granulocyte-colony stimulating factor priming.
    Fettah A; Özbek N; Azık F; Tavil B; Özgüner M; Avcı Z; Işık P; Yaralı N; Uçkan D; Tunç B
    Transfus Apher Sci; 2015 Jun; 52(3):332-8. PubMed ID: 25779226
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
    Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peripheral blood stem cell graft compared to bone marrow after reduced intensity conditioning regimens for acute leukemia: a report from the ALWP of the EBMT.
    Savani BN; Labopin M; Blaise D; Niederwieser D; Ciceri F; Ganser A; Arnold R; Afanasyev B; Vigouroux S; Milpied N; Hallek M; Cornelissen JJ; Schwerdtfeger R; Polge E; Baron F; Esteve J; Gorin NC; Schmid C; Giebel S; Mohty M; Nagler A
    Haematologica; 2016 Feb; 101(2):256-62. PubMed ID: 26565001
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-leukemic effect of graft-versus-host disease on bone marrow and extramedullary relapses in acute leukemia.
    Lee JH; Choi SJ; Lee JH; Seol M; Lee YS; Ryu SG; Park CJ; Chi HS; Lee MS; Yun S; Lee JS; Lee KH
    Haematologica; 2005 Oct; 90(10):1380-8. PubMed ID: 16219575
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype.
    Aversa F; Tabilio A; Velardi A; Cunningham I; Terenzi A; Falzetti F; Ruggeri L; Barbabietola G; Aristei C; Latini P; Reisner Y; Martelli MF
    N Engl J Med; 1998 Oct; 339(17):1186-93. PubMed ID: 9780338
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical study on haploid HLA-matched hematopoietic stem cell transplantation for treatment of malignant hematological disease].
    Sun AN; Wu DP; Wang Y; Qiu HY; Jin ZM; Miao M; Tang XW; Fu ZZ; Ma X; Han Y; He GS; Chen SN; Xue SL; Zhao Y
    Ai Zheng; 2006 Aug; 25(8):1019-22. PubMed ID: 16965686
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biomarkers for acute GVHD: can we predict the unpredictable?
    Chen YB; Cutler CS
    Bone Marrow Transplant; 2013 Jun; 48(6):755-60. PubMed ID: 22863728
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mycophenolate-based graft versus host disease prophylaxis is not inferior to methotrexate in myeloablative-related donor stem cell transplantation.
    Hamad N; Shanavas M; Michelis FV; Uhm J; Gupta V; Seftel M; Kuruvilla J; Lipton JH; Messner HA; Kim DD
    Am J Hematol; 2015 May; 90(5):392-9. PubMed ID: 25615933
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes in salivary proteome following allogeneic hematopoietic stem cell transplantation.
    Imanguli MM; Atkinson JC; Harvey KE; Hoehn GT; Ryu OH; Wu T; Kingman A; Barrett AJ; Bishop MR; Childs RW; Fowler DH; Pavletic SZ; Hart TC
    Exp Hematol; 2007 Feb; 35(2):184-92. PubMed ID: 17258067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased levels of syndecan-1 in serum during acute graft-versus-host disease.
    Seidel C; Ringdén O; Remberger M
    Transplantation; 2003 Jul; 76(2):423-6. PubMed ID: 12883204
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Growth factor-associated graft-versus-host disease and mortality 10 years after allogeneic bone marrow transplantation.
    Ringdén O; Labopin M; Gorin NC; Volin L; Torelli GF; Attal M; Jouet JP; Milpied N; Socié G; Cordonnier C; Michallet M; Atienza AI; Hermine O; Mohty M;
    Br J Haematol; 2012 Apr; 157(2):220-9. PubMed ID: 22299728
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.